Celcuity Reports Q1 Loss Beat, Expands Pivotal VIKTORIA-2 Trial for Gedatolisib

summarizeSummary

Celcuity Inc. reported a smaller-than-expected Q1 loss and significantly expanded its Phase 3 VIKTORIA-2 trial, broadening the potential market for its lead drug candidate, gedatolisib.

check_boxKey Events

• Q1 2026 Financial Results Beat Expectations

  Celcuity reported a smaller-than-expected Q1 loss, with adjusted EPS of -$0.86 significantly beating consensus estimates. Net cash used in operating activities increased to $55.1 million, with $387.1 million in cash and investments, providing a runway through 2027.

• Pivotal VIKTORIA-2 Trial Expanded

  The Phase 3 VIKTORIA-2 clinical trial was expanded to include a second study (Study 2) evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer, significantly broadening the drug's potential market.

• Subcutaneous Formulation Development Initiated

  Development of a subcutaneous formulation for gedatolisib is underway, with the first patent application submitted. This aims to provide a more convenient injection alternative to infusion, supporting long-term lifecycle development.

• FDA PDUFA Date Confirmed

  The FDA's Priority Review and PDUFA goal date of July 17, 2026, for gedatolisib's New Drug Application (NDA) in HR+/HER2- PIK3CA wild-type ABC was reconfirmed.

auto_awesomeAnalysis

This 8-K is highly important as it delivers a positive earnings surprise, with the company's adjusted Q1 loss beating analyst expectations. More critically, Celcuity announced a significant expansion of its pivotal Phase 3 VIKTORIA-2 trial to include a large, previously untapped patient population for first-line treatment of endocrine-sensitive breast cancer. This strategic move substantially increases the future market opportunity for gedatolisib. The company also confirmed its PDUFA date for another gedatolisib indication and is developing a more convenient subcutaneous formulation, reinforcing its long-term pipeline strategy.